Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eiger BioPharmaceuticals, Inc.EIGR · Entity 16554 | Director | March 01, 2023 | March 04, 2023 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP Chief Patient & Ext Af Off | July 21, 2026 | July 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eiger BioPharmaceuticals, Inc.
Report date March 01, 2023 · Filed March 04, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.71 · Expires 2033-02-28 | Direct | 28,000 |
Reported balance
After 2023-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-01 · Grant · Acquired 28,000 · Balance 28,000 F1: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date.
VERTEX PHARMACEUTICALS INC / MA
Report date July 21, 2026 · Filed July 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,512 |
Reported balance
After 2026-07-21 transaction · row 1
1 source rowRow 1 · 2026-07-21 · Grant · Acquired 8,251 · Balance 66,512 F1: Restricted stock unit award that vests on 03/31/2030. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 882 |
Reported balance
Holding disclosure · report date 2026-07-21 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 882 |
| Common StockSEC Table I · non-derivative | IndirectHeld in Trust | 6,637 |
Reported balance
Holding disclosure · report date 2026-07-21 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 6,637 |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock unit award that vests on 03/31/2030.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2016 Filed Feb 4, 2016 23:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,700 | $91.01 | $336,737.00 |
DisclosureSEC source: 0001209191-16-095843 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,262 F2 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F4 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $91.01 (range $90.37 to $91.35). Read SEC document |
| February 03, 2016 Filed Feb 4, 2016 23:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,300 | $89.91 | $386,613.00 |
DisclosureSEC source: 0001209191-16-095843 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,962 F2 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Open market sales reported on this line occurred at a weighted average price of $89.91 (range $89.31 to $90.27). F4 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 02, 2016 Filed Feb 4, 2016 23:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 34,482 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-16-095843 · doc4.xml · derivative · entry 7 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,482 Underlying: Common Stock · 34,482 shares Expires 2026-02-01 F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/02/2016. Read SEC document |
| February 02, 2016 Filed Feb 4, 2016 23:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 17,299 | $0.01 | $172.99 |
DisclosureSEC source: 0001209191-16-095843 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,262 F1 · shares: Restricted stock unit award that vests in three equal installments on 2/10/2017, 2/10/2018 and 2/10/2019. Read SEC document |
| November 16, 2015 Filed Nov 18, 2015 21:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 85 | $122.28 | $10,393.80 |
DisclosureSEC source: 0001209191-15-080955 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,963 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| October 30, 2015 Filed Nov 3, 2015 23:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,100 | $126.61 | $139,271.00 |
DisclosureSEC source: 0001209191-15-078180 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,963 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $126.61 (range $126.44 to $126.75). Read SEC document |
| October 30, 2015 Filed Nov 3, 2015 23:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,638 | $126.01 | $332,414.38 |
DisclosureSEC source: 0001209191-15-078180 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,063 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $126.01 (range $125.43 to $126.39). Read SEC document |
| October 30, 2015 Filed Nov 3, 2015 23:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,500 | $124.94 | $187,410.00 |
DisclosureSEC source: 0001209191-15-078180 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,701 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $124.94 (range $124.40 to $125.37). Read SEC document |
| October 30, 2015 Filed Nov 3, 2015 23:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 700 | $123.34 | $86,338.00 |
DisclosureSEC source: 0001209191-15-078180 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,201 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $123.34 (range $123.06 to $123.66). Read SEC document |
| July 21, 2015 Filed Jul 23, 2015 20:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 34,000 | $0.00 Strike: $131.89 | $0.00 |
DisclosureSEC source: 0001209191-15-062187 · doc4.xml · derivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2025-07-20 F1 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/21/2015. Read SEC document |
| May 15, 2015 Filed May 18, 2015 22:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 131 | $123.85 | $16,224.35 |
DisclosureSEC source: 0001209191-15-043942 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,901 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| March 23, 2015 Filed Mar 24, 2015 22:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $127.90 | $25,580.00 |
DisclosureSEC source: 0001209191-15-028969 · doc4.xml · nonDerivative · entry 8 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,901 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $127.90 (range $127.87 to $127.92). Read SEC document |
| March 23, 2015 Filed Mar 24, 2015 22:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 600 | $127.16 | $76,296.00 |
DisclosureSEC source: 0001209191-15-028969 · doc4.xml · nonDerivative · entry 7 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,101 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $127.16 (range $126.74 to $127.72). Read SEC document |
| March 23, 2015 Filed Mar 24, 2015 22:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,200 | $125.93 | $277,046.00 |
DisclosureSEC source: 0001209191-15-028969 · doc4.xml · nonDerivative · entry 6 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,701 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $125.93 (range $125.61 to $126.50). Read SEC document |
| March 23, 2015 Filed Mar 24, 2015 22:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,783 | $125.07 | $222,999.81 |
DisclosureSEC source: 0001209191-15-028969 · doc4.xml · nonDerivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,901 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $125.07 (range $124.56 to $125.51). Read SEC document |
| March 23, 2015 Filed Mar 24, 2015 22:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $122.78 | $36,834.00 |
DisclosureSEC source: 0001209191-15-028969 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,684 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $122.78 (range $122.46 to $123.24). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| March 20, 2015 Filed Mar 24, 2015 22:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 10,532 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-15-028969 · doc4.xml · derivative · entry 11 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,593 Underlying: Common Stock · 10,532 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2013. Read SEC document |
| March 20, 2015 Filed Mar 24, 2015 22:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 1,468 | $0.00 Strike: $48.74 | $0.00 |
DisclosureSEC source: 0001209191-15-028969 · doc4.xml · derivative · entry 10 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,032 Underlying: Common Stock · 1,468 shares Expires 2022-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/25/2012. Read SEC document |
| March 20, 2015 Filed Mar 24, 2015 22:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 12,000 | $135.08 | $1,620,960.00 |
DisclosureSEC source: 0001209191-15-028969 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,984 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| March 20, 2015 Filed Mar 24, 2015 22:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 10,532 | $45.11 | $475,098.52 |
DisclosureSEC source: 0001209191-15-028969 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2015 Filed Mar 24, 2015 22:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,468 | $48.74 | $71,550.32 |
DisclosureSEC source: 0001209191-15-028969 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 18, 2015 Filed Mar 20, 2015 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 6,625 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-15-028200 · doc4.xml · derivative · entry 6 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,125 Underlying: Common Stock · 6,625 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2013. Read SEC document |
| March 18, 2015 Filed Mar 20, 2015 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 5,375 | $0.00 Strike: $39.05 | $0.00 |
DisclosureSEC source: 0001209191-15-028200 · doc4.xml · derivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,375 shares Expires 2020-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| March 18, 2015 Filed Mar 20, 2015 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 12,000 | $130.00 | $1,560,000.00 |
DisclosureSEC source: 0001209191-15-028200 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,984 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| March 18, 2015 Filed Mar 20, 2015 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 6,625 | $45.11 | $298,853.75 |
DisclosureSEC source: 0001209191-15-028200 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 18, 2015 Filed Mar 20, 2015 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 5,375 | $39.05 | $209,893.75 |
DisclosureSEC source: 0001209191-15-028200 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2015 Filed Feb 20, 2015 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,137 | $113.14 | $354,920.18 |
DisclosureSEC source: 0001209191-15-016665 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,984 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $113.14 (range $112.95 to $113.78). Read SEC document |
| February 18, 2015 Filed Feb 20, 2015 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,800 | $112.62 | $315,336.00 |
DisclosureSEC source: 0001209191-15-016665 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,121 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $112.62 (range $111.94 to $112.91). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 03, 2015 Filed Feb 5, 2015 22:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (right to buy) · Derivative | 57,500 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-15-009898 · doc4.xml · derivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,500 Underlying: Common Stock · 57,500 shares Expires 2025-02-02 F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2015. Read SEC document |
| February 03, 2015 Filed Feb 5, 2015 22:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 17,250 | $0.01 | $172.50 |
DisclosureSEC source: 0001209191-15-009898 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,921 F1 · shares: Performance-based restricted stock award that will vest as to (i) 50% of the shares on the earlier to occur of (a) the attainment of a specified level of net product sales in the United States of lumacaftor in combination with ivacaftor over four calendar quarters and (b) the announcement of the results of a clinical trial establishing proof-of-concept for a next generation CFTR corrector and (ii) 50% of the shares on the earlier to occur of (a) the attainment of a specified level of net product sales outside of the United States of lumacaftor in combination with ivacaftor over four calendar quarters and (b) the announcement of the results from a successful pivotal clinical trial for a non-cystic fibrosis drug candidate sufficient to support the filing of an NDA. Read SEC document |
| January 09, 2015 Filed Jan 13, 2015 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $39.05 | $0.00 |
DisclosureSEC source: 0001209191-15-003894 · doc4.xml · derivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,375 Underlying: Common Stock · 12,000 shares Expires 2020-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| January 09, 2015 Filed Jan 13, 2015 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 12,000 | $125.00 | $1,500,000.00 |
DisclosureSEC source: 0001209191-15-003894 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,671 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| January 09, 2015 Filed Jan 13, 2015 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 12,000 | $39.05 | $468,600.00 |
DisclosureSEC source: 0001209191-15-003894 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 28, 2014 Filed Dec 1, 2014 22:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $39.05 | $0.00 |
DisclosureSEC source: 0001209191-14-071970 · doc4.xml · derivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,375 Underlying: Common Stock · 12,000 shares Expires 2020-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| November 28, 2014 Filed Dec 1, 2014 22:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 12,000 | $120.00 | $1,440,000.00 |
DisclosureSEC source: 0001209191-14-071970 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,671 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 28, 2014 Filed Dec 1, 2014 22:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 12,000 | $39.05 | $468,600.00 |
DisclosureSEC source: 0001209191-14-071970 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 17, 2014 Filed Nov 19, 2014 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 134 | $111.97 | $15,003.98 |
DisclosureSEC source: 0001209191-14-069995 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,671 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $111.97 (range $111.96 to $111.97). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| October 30, 2014 Filed Nov 3, 2014 22:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 40,000 | $0.01 | $400.00 |
DisclosureSEC source: 0001209191-14-065915 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,671 F1 · shares: Performance-based retention award that will vest if performance objectives are achieved prior to November 15, 2019. The award will vest on October 30, 2017 (or, if later, the day following the earnings release for the third quarter of 2017) if the Company achieves positive EBITDA for the 12-month period ending September 30, 2017. Between January 1, 2018 and November 15, 2019, if the Company achieves positive EBITDA for a 12-month period ending on a calendar quarter, the award will vest on the day following the applicable earnings release. Read SEC document |
| October 28, 2014 Filed Oct 30, 2014 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $39.05 | $0.00 |
DisclosureSEC source: 0001209191-14-065390 · doc4.xml · derivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,375 Underlying: Common Stock · 12,000 shares Expires 2020-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| October 28, 2014 Filed Oct 30, 2014 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 12,000 | $115.00 | $1,380,000.00 |
DisclosureSEC source: 0001209191-14-065390 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,671 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| October 28, 2014 Filed Oct 30, 2014 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 12,000 | $39.05 | $468,600.00 |
DisclosureSEC source: 0001209191-14-065390 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 28,594 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001209191-14-060588 · doc4.xml · derivative · entry 15 Sachdev Amit · CIK 0001406338 · SVP, Global Gov. Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,156 Underlying: Common Stock · 28,594 shares Expires 2022-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/02/2012. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 40,031 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0001209191-14-060588 · doc4.xml · derivative · entry 14 Sachdev Amit · CIK 0001406338 · SVP, Global Gov. Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,719 Underlying: Common Stock · 40,031 shares Expires 2021-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2011. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001209191-14-060588 · doc4.xml · derivative · entry 13 Sachdev Amit · CIK 0001406338 · SVP, Global Gov. Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,500 shares Expires 2020-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/14/2010. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 4,375 | $0.00 Strike: $39.05 | $0.00 |
DisclosureSEC source: 0001209191-14-060588 · doc4.xml · derivative · entry 12 Sachdev Amit · CIK 0001406338 · SVP, Global Gov. Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,375 Underlying: Common Stock · 4,375 shares Expires 2020-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/04/2010. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $33.28 | $0.00 |
DisclosureSEC source: 0001209191-14-060588 · doc4.xml · derivative · entry 11 Sachdev Amit · CIK 0001406338 · SVP, Global Gov. Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2019-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 17,247 | $113.91 | $1,964,605.77 |
DisclosureSEC source: 0001209191-14-060588 · doc4.xml · nonDerivative · entry 9 Sachdev Amit · CIK 0001406338 · SVP, Global Gov. Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,671 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $113.91 (range $113.62 to $114.40). Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 22,646 | $113.13 | $2,561,941.98 |
DisclosureSEC source: 0001209191-14-060588 · doc4.xml · nonDerivative · entry 8 Sachdev Amit · CIK 0001406338 · SVP, Global Gov. Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,918 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $113.13 (range $112.62 to $113.60). Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 34,753 | $112.22 | $3,899,981.66 |
DisclosureSEC source: 0001209191-14-060588 · doc4.xml · nonDerivative · entry 7 Sachdev Amit · CIK 0001406338 · SVP, Global Gov. Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,564 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $112.22 (range $111.62 to $112.61). Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 11,354 | $111.33 | $1,264,040.82 |
DisclosureSEC source: 0001209191-14-060588 · doc4.xml · nonDerivative · entry 6 Sachdev Amit · CIK 0001406338 · SVP, Global Gov. Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,317 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $111.33 (range $110.61 to $111.60). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.